Efficacy and safety of Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide Fumarate Tablets in treatment-naive acquired immune deficiency syndrome patients
- VernacularTitle:艾考恩丙替片对初治艾滋病患者的疗效及安全性评价
- Author:
Jinrong MO
1
;
Qiaoyu ZHOU
;
Jiong LIAO
;
Xiaoming LIAN
Author Information
- Publication Type:Research Article
- Keywords: Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide Fumarate Tablets; acquired immune deficiency syndrome; human immunodeficiency virus; quality of life; adherence
- From: Journal of Clinical Medicine in Practice 2024;28(12):100-106
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and safety of Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide Fumarate Tablets in initial treatment of acquired immune deficiency syndrome (AIDS) patients. Methods A total of 80 treatment-naive AIDS patients were selected as research subjects and randomly divided into control group and observation group, with 40 patients in each group. The control group was treated with free antiviral drugs (tenofovir + lamivudine + efavirenz), while the observation group was treated with Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide Fumarate Tablets. The CD4+ count, human immunodeficiency virus (HIV) viral load, and biochemical indicators were compared between the two groups before treatment and at 3, 6, 9, and 12 months after treatment. The adherence, adverse reactions, and quality of life were also compared between the two groups. Results During the treatment, six patients in the observation group and 9 patients in the control group had no compliance. With the extension of treatment time, the CD4+ level in both groups gradually increased, and the HIV viral load gradually decreased (
P < 0.05). After 3, 6, 9, and 12 months of treatment, the CD4+ levels in the observation group were higher than those in the control group, and the HIV viral loads were lower than those in the control group (P < 0.05). With the extension of treatment time, the levels of alanine aminotransferase, aspartate aminotransferase, urea, creatinine, and uric acid in the control group gradually increased, and the random blood glucose levels after 3, 6, 9, and 12 months of treatment in the control group were higher than those before treatment (P < 0.05). After 3, 6, 9, and 12 months of treatment, the levels of alanine aminotransferase, aspartate aminotransferase, urea, creatinine, uric acid, and random blood glucose in the observation group were lower than those in the control group (P < 0.05). The incidence of adverse reactions in the observation group was 2.94% (1/34), which was lower than 90.00% (36/40) in the control group (correctedχ 2=55.718,P < 0.001). With the extension of treatment time, the scores of various dimensions of quality of life in both groups gradually increased, and the scores of various dimensions of quality of life after treatment in the observation group were higher than those in the control group (P < 0.05). Conclusion Compared with the free antiviral drug regimen, Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide Fumarate Tablets shows better efficacy in the treatment of AIDS-naive patients, which can significantly increase the CD4+ level, and reduce the HIV viral load. Besides, it has high safety, and can significantly improve their quality of life.
